文献速递前列腺癌

根治性前列腺切除术对根据STAMPEDE标准筛选的高危非转移性前列腺癌男性生存的影响:一项EMPaCT研究

Effect of Radical Prostatectomy on Survival for Men with High-risk Nonmetastatic Prostate Cancer Features Selected According to STAMPEDE Criteria: An EMPaCT Study.
PubMed 文献 · Eur Urol Oncol · 2024-07-14

这项回顾性多中心队列研究纳入2994例接受根治性前列腺切除术和扩大盆腔淋巴结清扫的欧洲泌尿外科学会(EAU)高危前列腺癌患者,按STAMPEDE高危因素(SHRF)数目分组。10年癌症特异性生存(CSS)在0-1个SHRF组为95%、2-3个SHRF组为82%;总生存(OS)分别为81%和64%(均p<0.0001)。作者认为手术仍是STAMPEDE高危前列腺癌患者的可行治疗选择。

要点

  • 0-1个SHRF组10年CSS为95%,2-3个SHRF组为82%(p<0.0001)。
  • 0-1个SHRF组10年OS为81%,2-3个SHRF组为64%(p<0.0001)。
  • 作者认为手术仍是STAMPEDE高危前列腺癌患者的可行治疗选择。

核心结论

  • STAMPEDE高危标准可识别出具有高度侵袭性前列腺癌特征和不良长期肿瘤学结局的患者亚组。
  • 该人群可能从积极的多模式治疗中获益最大。
  • 作者首次显示手术仍是STAMPEDE高危前列腺癌患者的可行治疗选择。

研究设计与样本

  • 回顾性、多中心队列研究,纳入接受根治性前列腺切除术和扩大盆腔淋巴结清扫的EAU高危前列腺癌患者2994例。
  • 按STAMPEDE高危因素(SHRF)数目分为0、1、2、3个SHRF组。
  • 采用累积发生率曲线评估CSS,Kaplan-Meier法评估OS,Fine and Gray模型评估SHRF对CSS的预后价值,Cox比例风险模型评估SHRF与OS的关联。

主要发现

  • 0-1个SHRF组 vs 2-3个SHRF组的10年CSS为95% vs 82%(p<0.0001)。
  • 0-1个SHRF组 vs 2-3个SHRF组的10年OS为81% vs 64%(p<0.0001)。
  • 与0个SHRF组相比,1、2、3个SHRF组的CSS风险比分别为1.2(p=0.5)、3.9(p<0.0001)、5.5(p<0.0001)。
  • 与0个SHRF组相比,1、2、3个SHRF组的OS风险比分别为1.1(p=0.4)、2.2(p<0.0001)、2.5(p=0.0004)。

临床怎么用

  • 作者认为STAMPEDE高危标准识别的患者亚组可能从积极的多模式治疗中获益最大。
  • 作者认为手术仍是STAMPEDE高危前列腺癌患者的可行治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: A meta-analysis of two randomized STAMPEDE platform trials revealed that 3 yr of abiraterone acetate in addition to androgen deprivation therapy and radiation therapy significantly improved metastasis-free and overall survival (OS) in high-risk nonmetastatic prostate cancer (PCa) and should be considered a new standard of care. The aim of our study was to assess long-term cancer-specific survival (CSS) and OS for surgically treated patients with newly diagnosed nonmetastatic node-negative PCa meeting the STAMPEDE criteria for high risk. METHODS: This was a retrospective, multicenter cohort study of patients with European Association of Urology (EAU) high-risk PCa who underwent radical prostatectomy and extended pelvic lymph node dissection. CSS was assessed using cumulative incidence curves and the Kaplan-Meier method was used to evaluate OS. We used a Fine and Gray model to evaluate the prognostic value of STAMPEDE high-risk factors (SHRFs) for CSS, and a Cox proportional-hazards model to assess the association of SHRFs with OS. KEY FINDINGS AND LIMITATIONS: A total of 2994 patients with EAU high-risk PCa were divided into groups with 0, 1, 2, or 3 SHRFs. The 10-yr survival estimates for patients with 0-1 versus 2-3 SHRFs were 95% versus 82% for CSS and 81% versus 64% for OS (both p < 0.0001). In comparison to patients with 0 SHRFs, hazard ratios were 1.2 (p = 0.5), 3.9 (p < 0.0001), and 5.5 (p < 0.0001) for CSS, and 1.1 (p = 0.4), 2.2 (p < 0.0001), and 2.5 (p = 0.0004) for OS for patients with 1, 2, and 3 SHRFs, respectively. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our results confirm that the STAMPEDE high-risk criteria identify a subgroup of patients with highly aggressive PCa features and adverse long-term oncological outcomes. This population is likely to benefit most from aggressive multimodal treatment. Nevertheless, we have shown for the first time that surgery remains a viable treatment option for patients with STAMPEDE high-risk PCa. PATIENT SUMMARY: Prostate cancer that meets the high-risk definitions from the STAMPEDE trial is an aggressive type of cancer. Our results for long-term cancer control outcomes indicate that surgery is a viable option for the subgroup of patients with this type of prostate cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Milonas D, Giesen A, Laenen A, et al. Effect of Radical Prostatectomy on Survival for Men with High-risk Nonmetastatic Prostate Cancer Features Selected According to STAMPEDE Criteria: An EMPaCT Study. Eur Urol Oncol. 2024. PMID: 38997858. doi:10.1016/j.euo.2024.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。